Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Stock analysts at William Blair dropped their Q1 2025 EPS estimates for shares of Arcturus Therapeutics in a research note issued on Thursday, March 13th. William Blair analyst M. Minter now forecasts that the biotechnology company will post earnings per share of ($1.39) for the quarter, down from their prior estimate of ($0.53). The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics' Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.31) EPS, Q1 2026 earnings at ($1.39) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.52) EPS, Q4 2026 earnings at ($1.59) EPS, FY2026 earnings at ($5.98) EPS and FY2027 earnings at $0.41 EPS.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). The company had revenue of $22.77 million during the quarter, compared to analysts' expectations of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%.
ARCT has been the topic of a number of other reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a research note on Monday, March 10th. HC Wainwright decreased their price objective on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Canaccord Genuity Group reduced their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Finally, Wells Fargo & Company dropped their price objective on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $59.20.
Check Out Our Latest Analysis on Arcturus Therapeutics
Arcturus Therapeutics Price Performance
Arcturus Therapeutics stock traded down $0.65 during midday trading on Monday, reaching $12.75. The company had a trading volume of 248,403 shares, compared to its average volume of 454,981. The company has a market capitalization of $345.78 million, a P/E ratio of -5.74 and a beta of 2.96. Arcturus Therapeutics has a 12-month low of $12.65 and a 12-month high of $45.00. The firm's fifty day simple moving average is $16.29 and its 200-day simple moving average is $18.16.
Hedge Funds Weigh In On Arcturus Therapeutics
A number of large investors have recently bought and sold shares of the stock. Wellington Management Group LLP grew its holdings in Arcturus Therapeutics by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company's stock valued at $1,647,000 after purchasing an additional 742 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company's stock valued at $202,000 after purchasing an additional 846 shares during the last quarter. Ameriprise Financial Inc. lifted its position in Arcturus Therapeutics by 5.0% in the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock valued at $316,000 after purchasing an additional 883 shares during the last quarter. Virtus ETF Advisers LLC lifted its position in Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 1,132 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Arcturus Therapeutics by 7.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company's stock valued at $323,000 after buying an additional 1,279 shares during the period. Hedge funds and other institutional investors own 94.54% of the company's stock.
About Arcturus Therapeutics
(
Get Free Report)
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Recommended Stories
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
